Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Summit will to advance the clinical development of SMT112 (ivonescimab), a novel, potential first-in-class investigational bispecific antibody, in non-small cell lung cancer (NSCLC).
Lead Product(s): Ivonescimab,Carboplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 03, 2024
Details:
Ivonescimab, known as AK112 in China and Australia, is a novel, first-in-class, approved bispecific antibody blocking PD-1 with VEGF for treating EGFR-mutated, advanced non-squamous NSCLC.
Lead Product(s): Ivonescimab,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: AK112
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2024
Details:
Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody inhibiting PD-1 with VEGF is being investiated for PD-L1-positive NSCLC.
Lead Product(s): Ivonescimab
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2024
Details:
SMT112 (ivonescimab) is a potential first-in-class investigational PD-1/VEGF bi-specific antibody, which is investigated for the treatment of first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.
Lead Product(s): Ivonescimab
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Akeso
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
SMT112 (Ivonescimab) is a potential first-in-class investigational PD-1/VEGF bi-specific antibody, which is investigated for the treatment of first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.
Lead Product(s): Ivonescimab
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Akeso
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2023
Details:
SMT112 (ivonescimab) is an investigational bispecific antibody which blocks PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. It is being investigated for EGFR mutated NSCLC.
Lead Product(s): Ivonescimab,Carboplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
SMT112 (ivonescimab) is a novel, potential first-in-class, investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule.
Lead Product(s): Ivonescimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
The net proceeds will be used to support the development of SMT112. Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody. Engineered with Tetrabody technology, ivonescimab blocks PD-1 binding to PD-L1 and PD-L2, and blocks VEGF binding to VEGF receptors.
Lead Product(s): Ivonescimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 03, 2023
Details:
The net proceeds will be used to support the development of SMT112. Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody. Engineered with Tetrabody technology, ivonescimab blocks PD-1 binding to PD-L1 and PD-L2, and blocks VEGF binding to VEGF receptors.
Lead Product(s): Ivonescimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 30, 2023
Details:
Under the terms of agreement, Summit will receive the rights to develop and commercialize SMT112/AK112 (ivonescimab), a novel, potential first-in-class bispecific antibody, in the U.S.A, Canada, Europe, and Japan and Akeso will retain rights for the rest of the world.
Lead Product(s): Ivonescimab
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Akeso
Deal Size: $5,000.0 million Upfront Cash: $500.0 million
Deal Type: Licensing Agreement January 20, 2023